CALLABLE DEFENDER VONTI - IDORSIA | Market Closed - Swiss Exchange 16:20:00 24/05/2024 BST | ||
| 94 CHF | -0.11% |
|
| Current month | +2.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 94 | -0.11% |
| 22/05/24 | 94.1 | +0.11% |
| 21/05/24 | 94 | -0.63% |
| 17/05/24 | 94.6 | -0.63% |
Delayed Quote Swiss Exchange
Last update May 24, 2024 at 04:20 pm
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | 
Vontobel
|
| RIDACV | |
| ISIN | CH1333289291 |
| Date issued | 19/04/2024 |
| Strike | 1.97 CHF |
| Maturity | 22/04/2025 (331 Days) |
| Parity | 0 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | both |
| Currency | CHF |
Technical Indicators
| Highest since issue | 95.4 CHF |
|---|---|
| Lowest since issue | 91.8 CHF |
| Spread | 8 CHF |
| Spread % | 0.85% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.15
CHF
Average target price
1.692
CHF
Spread / Average Target
-21.28%
- Stock Market
- Certificates
- RIDACV Certificat
